Incidence of END24 in non-thrombolysed patients with AIS
| Study | Inclusion criteria | N | Def. of END24 | Percentage of END24 | Percentage of END24 due to sICH |
|---|---|---|---|---|---|
| Dávalos et al18 | AIS <8 h | 98 | CNS ≤1 | 31.6 | NA |
| Camerlingo et al20* | MCA-AIS <5 h | 45 | CNS ≤1 | 13.3 | 16.7 |
| Toni et al21 | MCA-AIS <5 h | 152 | CNS ≤1 | 15.1 | NA |
| Dávalos et al23† | AIS <6 h | 305 | SSS‡ | 36.8 | 7.1§ |
| Alexandrov et al25 | AIS <6 h, NIHSS <4 | 50 | NIHSS ≥4 | 16.3 | NA |
| Grotta et al27¶ | AIS <3 h | 312 | NIHSS ≥4 | 17.6 | 3.6§ |
*Therapeutic study, with immediate intravenous heparin therapy.
†Placebo group of ECASSI study.
‡END was defined by a decrease of ≥3 points for speech, or ≥2 points for consciousness or arm, hand or leg motor power at the SSS.
§Information extracted from Hacke et al.53
¶Placebo group of NINDS IV-rtPA stroke trial study.
AIS, Acute ischaemic stroke; CNS, Canadian Neurological Scale; ECASSI, The European Cooperative Acute Stroke Study; END24, early neurological deterioration within 24 h of acute ischaemic stroke; MCA-AIS, middle cerebral artery-AIS; NA, not assessed; NIHSS, National Institutes of Health Stroke Scale; sICH, symptomatic intracranial haemorrhage; SSS, Scandinavian Stroke Scale.